Found: 16
Select item for more details and to access through your institution.
Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 11, p. 1, doi. 10.1093/ofid/ofac618
- By:
- Publication type:
- Article
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-32551-2
- By:
- Publication type:
- Article
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 5, p. 658, doi. 10.7326/M22-3428
- By:
- Publication type:
- Article
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 3, p. 348, doi. 10.7326/M22-2381
- By:
- Publication type:
- Article
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 4, p. e2310039, doi. 10.1001/jamanetworkopen.2023.10039
- By:
- Publication type:
- Article
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 6, p. 1207, doi. 10.1002/cpt.2706
- By:
- Publication type:
- Article
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
- Published in:
- Clinical Infectious Diseases, 2023, v. 77, n. 7, p. 941, doi. 10.1093/cid/ciad342
- By:
- Publication type:
- Article
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 4, p. 734, doi. 10.1093/cid/ciac818
- By:
- Publication type:
- Article
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S101, doi. 10.1093/infdis/jiad285
- By:
- Publication type:
- Article
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S83, doi. 10.1093/infdis/jiad300
- By:
- Publication type:
- Article
Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S117, doi. 10.1093/infdis/jiad287
- By:
- Publication type:
- Article
Long COVID After Bamlanivimab Treatment.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S126, doi. 10.1093/infdis/jiad286
- By:
- Publication type:
- Article
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S77, doi. 10.1093/infdis/jiad246
- By:
- Publication type:
- Article
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.
- Published in:
- Journal of Infectious Diseases, 2023, v. 288, p. S92, doi. 10.1093/infdis/jiad209
- By:
- Publication type:
- Article
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
- Published in:
- Journal of Infectious Diseases, 2023, v. 228, n. 2, p. 133, doi. 10.1093/infdis/jiad013
- By:
- Publication type:
- Article